The Costs of Non-Muscle Invasive Bladder Cancer

Andrew C. James, John L. Gore

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Bladder cancer is a common diagnosis, affecting 70,000 Americans each year. Because the diagnosis, management, and long-term follow-up of non-muscle invasive bladder cancer requires advanced imaging and invasive testing, economic evaluations have shown bladder cancer to be the costliest cancer to treat in the US on a per capita basis. Adjunctive tests for surveillance have not obviated the need for cystoscopy and cytology. Indirect costs to patients include loss of work, decreased productivity, and diminished quality of life associated with diagnosis, treatment, and surveillance. Improved value may be achieved with better compliance with evidence-based practices for non-muscle invasive bladder cancer care.

Original languageEnglish
Pages (from-to)261-269
Number of pages9
JournalUrologic Clinics of North America
Issue number2
StatePublished - May 2013


  • Bladder cancer
  • Cost-effectiveness
  • Quality of care

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The Costs of Non-Muscle Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this